An Alberta-based licensed producer claims it’s the first company to make a cannabis suppository available to medical patients across Canada through its partnership with member site Shelter Market. Prairie Grass Inc., the founding sisters of which grew up on a family farm spanning four generations of regenerative and sustainable farming, is offering two formulations.
The “Relief Pods” produced from a “Bruce Banner” cultivar grown in the company’s facility provide 10 mg THC, while “Eve Pods” have 40 mg CBD and are made from Prairie Grass’ outdoor hemp harvest. The products, which are batch-tested and safety-tested formulations, have “been specifically formulated to provide localized relief, with targeted dosing directly to the pelvis and surrounding region,” notes a company statement. Both Thomson and Penner believe that “suppositories are an overlooked delivery mechanism for providing effective, targeted pain relief,” the statement notes.
Project CBD, a California-based non-profit dedicated to promoting and publicizing research into the medical uses of CBD, notes that clinical research on cannabis suppositories remains limited. But “anecdotal accounts from patients are often very positive,” with the lack of intoxication an oft-repeated report.
“This suggests that a suppository acts more like a topical with a local effect, rather than a transdermal patch which disseminates medicine systemically through the bloodstream,” the group explains.
Prairie Grass explains that cannabinoids administered vaginally or rectally bypass the digestive tract and first-pass metabolism in the liver, going directly to the bloodstream. “This can help facilitate a higher absorption rate of cannabinoids in the body,” the company statement adds.
While the potential market for cannabis suppositories may be big, Canada seems to have been slow to get related products on store shelves.
As it stands, cannabis extracts cover a broad range of product types and intended uses, notes information from the Government of Canada. These include products that are smoked or inhaled, ingested or inserted, such as suppositories.
In general, the production of packaged units of cannabis extracts was almost 2.8 million in March of 2021, add figures from the federal government. Of those, medical sales amounted to $262,683 compared to $1.7 million for non-medical.